This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A randomised phase III placebo-controlled trial ev...
Clinical trial

A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder

Read time: 1 mins
Last updated:23rd Jul 2006
The main objectives of the trial are to determine if the addition of the oral COX-2 inhibitor celecoxib to standard therapy is more effective in terms of disease recurrence at 3 years than standard therapy alone for the treatment of superficial TCC of the bladder at high risk of recurrence. To determine if the addition of the oral COX-2 inhibitor celecoxib to standard therapy is more effective in terms of disease recurrence at 3 years than standard therapy alone for the treatment of superficial TCC of the bladder at intermediate risk of recurrence.
Category Value
Study start date 2006-07-23

View full details